Name: CytomX Therapeutics, Inc. (CTMX) Cash Flow Statement
Creator: FinSpry

CytomX Therapeutics Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scale:

Scroll to see more

Cash flow statement showing operating, investing, and financing activities for CytomX Therapeutics, Inc. (CTMX) - Annual data in millions USD
Breakdown	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018
Period Ending	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018
Operating Activities
Net Income	31.87	-0.57	-99.32	-115.87	-64.82	-102.24	-84.60
Depreciation & Amortization	1.77	2.18	2.39	2.71	2.57	0.38	1.88
Stock Based Compensation	7.67	8.56	13.13	13.17	14.79	0.00	0.00
Change in Working Capital	-126.42	-55.47	-20.87	-22.44	50.07	-46.60	-7.98
Change in Accounts Receivable	0.33	32.55	-35.20	0.01	-0.79	0.00	0.00
Change in Accounts Payable	-0.30	-1.43	0.07	-0.14	-0.86	0.00	0.00
Change in Other Working Capital	-8.20	3.73	-12.09	11.64	-11.12	0.00	0.00
Other Operating Activities	4.08	-2.17	6.75	3.13	2.89	7.98	0.00
Net Cash from Operating Activities	-86.23	-56.04	-110.79	-119.03	5.26	-140.48	-75.52
Investing Activities
Capital Expenditures	-0.31	0.84	1.74	-1.61	-2.31	3.50	-3.79
Purchases of Investments	100.01	-424.83	100.00	24.10	-16.41	0.00	0.00
Sales/Maturities of Investments	255.50	275.00	100.00	124.00	-16.41	83.20	9.71
Net Cash from Investing Activities	99.70	-150.67	98.26	22.49	-18.72	79.70	5.93
Financing Activities
Common Stock Issued	7.52	0.56	0.65	110.21	16.89	0.00	134.60
Other Financing Activities	0.61	29.67	0.00	0.00	0.00	0.00	0.00
Net Cash from Financing Activities	7.52	30.23	0.65	110.21	16.89	1.63	139.62
Summary
Net Change in Cash	20.99	-176.48	-11.88	13.67	3.43	-59.15	70.03
Cash at Beginning of Period	18.09	194.57	206.45	192.78	189.34	248.49	178.47
Cash at End of Period	39.08	-56.88	194.57	206.45	192.78	189.34	248.49
Free Cash Flow	-86.54	-56.88	-112.53	-120.64	2.95	-143.98	-79.31
Supplemental Disclosures
Income Taxes Paid	0.00	0.00	0.00	0.00	0.00	13.06	0.00